Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies

PLoS One. 2018 Nov 16;13(11):e0205743. doi: 10.1371/journal.pone.0205743. eCollection 2018.

Abstract

Background: Zika virus (ZIKV) is an emerging pathogen with no approved therapeutics and only limited diagnostics available. To address this gap, six mouse single-chain antibodies (scFvs) to ZIKV envelope (E) protein were isolated rapidly and efficiently from a ribosome-displayed antibody library constructed from the spleens of five immunized mice.

Methodology/results: In this report, we have generated a panel of mouse scFvs to ZIKV E protein using ribosome display. The six scFvs demonstrated no cross-reactivity with DENV2 NGC envelope protein, suggesting specificity for ZIKV E protein. These scFvs showed differences in their affinity: two (scFv45-3, scFv63-1) of them were dominant after four rounds of panning, and showed higher affinity (an apparent Kd values from 19 to 27 nM) than the other four (scFv5-1, scFv7-2, scFv38-1, and scFv51-2). All six scFvs showed ZIKV-neutralizing activity in the plaque reduction neutralization test (PRNT) assay and their neutralizing activity was positively correlated with their affinities.

Conclusions/significance: The scFvs (45-3 and 63-1) with highest affinity may have dual utility as diagnostics capable of recognizing ZIKV E subtypes and may be further developed to treat ZIKV infection. Our approach has the added advantage of generating Fc receptor-deficient antibodies, minimizing concern of antibody-dependent enhancement (ADE) of infection.

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Neutralizing / therapeutic use
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use
  • Antibody-Dependent Enhancement / immunology
  • Humans
  • Immunoglobulin G / genetics
  • Immunoglobulin G / immunology
  • Mice
  • Ribosomes / genetics*
  • Ribosomes / immunology
  • Single-Chain Antibodies / immunology*
  • Single-Chain Antibodies / therapeutic use
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology
  • Zika Virus / drug effects*
  • Zika Virus / immunology
  • Zika Virus / pathogenicity
  • Zika Virus Infection / diagnosis
  • Zika Virus Infection / immunology*
  • Zika Virus Infection / therapy

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin G
  • Single-Chain Antibodies
  • Viral Envelope Proteins

Grants and funding

The authors received no specific funding for this work.